Allergy Therapeutics to present at EAACI 2026

12 June 2026 - Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, today announces that it will be presenting data from across its pollen and food allergy research portfolio at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, taking place in Istanbul, Türkiye, from today, through to 15 June 2026.

The EAACI Congress is the world's largest scientific conference specialising in the field of allergy and clinical immunology and the flagship meeting of the European Academy of Allergy and Clinical Immunology. The Academy is an association of more than 16,000 clinicians, researchers and allied health professionals from 124 countries, dedicated to improving the health of people affected by allergic diseases.

Allergy Therapeutics will present 15 posters and oral presentations at the conference, including:

• Data from the Group's Phase I/IIa PROTECT trial of VLP Peanut, the Group's innovative, short-course peanut allergy immunotherapy candidate. The PROTECT trial met the primary endpoint, demonstrating a benign safety profile of VLP Peanut, with a strong dose-response in immunomodulating tolerogenic immune responses induced confirming clinical proof of concept.
• Blinded safety data from the first year of the Company's G308 Phase III trial evaluating the short- and long-term efficacy and safety of Grass MATA MPL in a paediatric population with grass-induced seasonal allergic rhinitis and rhinoconjunctivitis, demonstrating a benign safety profile in the first year of treatment and a low trial discontinuation rate.

The Company will also host a symposium at the EAACI Congress today from 15:00-16:00 TRT, co-chaired by Dr. Mohamed Shamji, Professor of Immunology and Allergy at Imperial College London, and Dr. Janice Layhadi, Research Associate at the Immunomodulation and Tolerance Group of Allergy & Clinical Immunology, Imperial College London. The symposium, titled Scoring Against Allergies: New Therapeutic Strategies on the Horizon, will focus on Allergy Therapeutics' ongoing work with Grass MATA MPL in a paediatric population and highlight the Company's progression of VLP Peanut as a novel therapeutic candidate for peanut allergy.

In addition, the EAACI Early Career Research Award, supported by Allergy Therapeutics, will be presented to this year's recipient, Juan Luis Paris, PhD, at this year's congress. Juan Luis is a Principal Investigator at the Instituto de Investigación Biomédica de Málaga (IBIMA, Málaga, Spain), where his research is focused on developing bio- and nano-materials for therapeutic immunomodulation in allergic diseases and other pathologies. The EAACI Early Career Research Award provides an unrestricted research grant of up to €30,000 and is open to EAACI Junior Members who have previously published their high-impact research on allergy and immunology and demonstrated their drive and dedication in the area of immunotherapy.

Manuel Llobet, Chief Executive Officer at Allergy Therapeutics, said: "We are pleased to have a strong presence at this year's EAACI Congress, a key scientific event in allergy and clinical immunology. The 15 posters and oral presentations, our symposium and continued support of the EAACI Early Career Research Award reflect not only the progress made across our clinical portfolio, but also our team's commitment to advancing broader scientific understanding and empowering research across the field.

"Data from our Phase I/IIa PROTECT trial of VLP Peanut have confirmed a strong safety and tolerability profile of this novel immunotherapy candidate while also demonstrating clinical proof of concept, and we are continuing our preparations for the Group's Phase IIb trial. Clinical progress with Grass MATA MPL has continued following regulatory approval of the product in Germany, with encouraging paediatric safety data strengthening our evidence base that the product could provide a differentiated treatment option for grass-induced seasonal allergic rhinitis and rhinoconjunctivitis in a younger patient population.

"We look forward to discussing our progress with colleagues at the conference and continuing our mission to deliver innovative, disease-modifying therapies for allergy sufferers worldwide."

The complete list of Allergy Therapeutics-sponsored abstracts accepted by EAACI for presentation are available on the Group's website.

No new material price sensitive information will be disclosed on Allergy Therapeutics at the EAACI Congress 2026.